- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib ; volume:8 ; number:1 ; day:17 ; month:1 ; year:2018 ; pages:1-7 ; date:12.2018
Scientific reports ; 8, Heft 1 (17.1.2018), 1-7, 12.2018
- Urheber
-
Caiola, Elisa
- Beteiligte Personen und Organisationen
-
Frapolli, Roberta
Tomanelli, Michele
Valerio, Rossana
Iezzi, Alice
Garassino, Marina C.
Broggini, Massimo
Marabese, Mirko
SpringerLink (Online service)
- DOI
-
10.1038/s41598-017-18900-y
- URN
-
urn:nbn:de:1111-2018041121570
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Caiola, Elisa
- Frapolli, Roberta
- Tomanelli, Michele
- Valerio, Rossana
- Iezzi, Alice
- Garassino, Marina C.
- Broggini, Massimo
- Marabese, Mirko
- SpringerLink (Online service)
Ähnliche Objekte (12)
15-year remission in refractory FLT3-mutated AML attained by sorafenib
15-year remission in refractory FLT3-mutated AML attained by sorafenib
Camptothecin Sensitizes Hepatocellular Carcinoma Cells to Sorafenib- Induced Ferroptosis Via Suppression of Nrf2
Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
Untangling the KRAS mutated lung cancer subsets and its therapeutic implications
Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC
Spatial iTME analysis of KRAS mutant NSCLC and immunotherapy outcome
Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report
Sotorasib in KRAS p.G12C-Mutated Pulmonary Sarcomatoid Carcinoma: Therapeutic Efficacy of a KRAS Inhibitor in Symptomatic Brain Metastases
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
Somatically mutated ABL 1 is an actionable and essential NSCLC survival gene
15-year remission in refractory FLT3-mutated AML attained by sorafenib
15-year remission in refractory FLT3-mutated AML attained by sorafenib
Camptothecin Sensitizes Hepatocellular Carcinoma Cells to Sorafenib- Induced Ferroptosis Via Suppression of Nrf2
Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
Untangling the KRAS mutated lung cancer subsets and its therapeutic implications
Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC
Spatial iTME analysis of KRAS mutant NSCLC and immunotherapy outcome
Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report
Sotorasib in KRAS p.G12C-Mutated Pulmonary Sarcomatoid Carcinoma: Therapeutic Efficacy of a KRAS Inhibitor in Symptomatic Brain Metastases
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
Somatically mutated ABL 1 is an actionable and essential NSCLC survival gene
15-year remission in refractory FLT3-mutated AML attained by sorafenib
15-year remission in refractory FLT3-mutated AML attained by sorafenib
Camptothecin Sensitizes Hepatocellular Carcinoma Cells to Sorafenib- Induced Ferroptosis Via Suppression of Nrf2
Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
Untangling the KRAS mutated lung cancer subsets and its therapeutic implications
Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC
Spatial iTME analysis of KRAS mutant NSCLC and immunotherapy outcome
Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report
Sotorasib in KRAS p.G12C-Mutated Pulmonary Sarcomatoid Carcinoma: Therapeutic Efficacy of a KRAS Inhibitor in Symptomatic Brain Metastases
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC